Meningitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Meningitis – Drugs In Development, 2024 report and make more profitable business decisions.
Meningitis is the inflammation of the meninges, protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life-threatening, depending on its cause. Viral meningitis is not life-threatening; those affected can be recover quickly. Bacterial meningitis is serious and life-threatening. The three major bacteria are Neisseria meningitides, which causes meningococcal meningitis; pneumococcal meningitis is caused by the bacteria streptococcus pneumonia; and haemophilius influenza causes meningitis in infants. 44–46% of cases of bacterial meningitis have all of the following three symptoms: severe headache, nuchal ridgidity (inability to flex the neck forward), and altered mental status. Severe headache occurs in 90% of the cases.
Other symptoms include photophobia (fear of bright light) and phonophobia (fear of loud noises). In infants up to 6 months, bulging of the fontanelle (soft spot on the baby’s head) may be visible. Less severe symptoms, including extreme cold, abnormality in skin color, and leg pain, may also be distinguishing features for meningitis.
The Meningitis drugs in development market research report provide comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Meningitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Meningitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Meningitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Meningitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AIM Vaccine Co LtdAmtixbio Co Ltd
CanSino Biologics Inc
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Cipla Ltd
Drugs for Neglected Diseases initiative
Griffith University
Institute of Medical Biology Chinese Academy of Medical Sciences
Jiangsu Kunli Biopharmaceutical Co Ltd
LG Chem Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Pfizer Inc
Second Military Medical University
Serum Institute of India Pvt Ltd
Suzhou Weichao Biotechnology Co Ltd
Texas A&M University
Yisheng Biopharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Meningitis reports